Bao JF, She QY, Hu PP, Jia N, Li A. Irisin, a fascinating field in our times. Trends Endocrinol Metab. 2022;33:601–13.

Article  CAS  PubMed  Google Scholar 

Yu Q, Kou W, Xu X, Zhou S, Luan P, Xu X, et al. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci. 2019;133:611–27.

Article  CAS  Google Scholar 

Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.

Article  PubMed  PubMed Central  Google Scholar 

Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61:1725–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Y, Chen Q, Jiang Q, Zhao Z, Fang J, Chen L. Irisin lowers blood pressure in Zucker diabetic rats by regulating the functions of renal angiotensin II type 1 receptor via the inhibition of the NF-κB signaling pathway. Peptides. 2022;147:170688.

Article  CAS  PubMed  Google Scholar 

Fu J, Han Y, Wang J, Liu Y, Zheng S, Zhou L, et al. Irisin lowers blood pressure by improvement of endothelial dysfunction via AMPK-Akt-eNOS-NO pathway in the spontaneously hypertensive rat. J Am Heart Assoc. 2016;5:e003433.

Article  PubMed  PubMed Central  Google Scholar 

Huo CJ, Yu XJ, Sun YJ, Li HB, Su Q, Bai J, et al. Irisin lowers blood pressure by activating the Nrf2 signaling pathway in the hypothalamic paraventricular nucleus of spontaneously hypertensive rats. Toxicol Appl Pharmacol. 2020;394:114953.

Article  CAS  PubMed  Google Scholar 

Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with chronic kidney disease. PLoS One. 2013;8:e64025.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gan W, Chen W, Li T, Shao D, Xu F, Huo S, et al. Circulating irisin level in chronic kidney disease patients: a systematic review and meta-analysis. Int Urol Nephrol. 2022;54:1295–302.

Article  CAS  PubMed  Google Scholar 

Liu JJ, Liu S, Wong MD, Tan CS, Tavintharan S, Sum CF, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications. 2014;28:208–13.

Article  PubMed  Google Scholar 

Ebert T, Focke D, Petroff D, Wurst U, Richter J, Bachmann A, et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol. 2014;170:501–6.

Article  CAS  PubMed  Google Scholar 

Lee MJ, Lee SA, Nam BY, Park S, Lee SH, Ryu HJ, et al. Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients. Atherosclerosis. 2015;242:476–82.

Article  CAS  PubMed  Google Scholar 

Kałużna M, Pawlaczyk K, Schwermer K, Hoppe K, Człapka-Matyasik M, Ibrahim AY, et al. Adropin and irisin: new biomarkers of cardiac status in patients with end-stage renal disease? A preliminary study. Adv Clin Exp Med. 2019;28:347–53.

Article  PubMed  Google Scholar 

Wang PX, Fan ZJ, Wu LY, Wang SY, Zhang JL, Dong XT, et al. Serum irisin levels are negatively associated with blood pressure in dialysis patients. Hypertens Res. 2023. https://doi.org/10.1038/s41440-023-01449-x.